Helping to Bring Improved and Novel Therapies to the Right Patient Population Faster

NTRC ONCOLINES™

Access Cancer Cell Line Proliferation Assays to Identify Predictive Drug Response Biomarkers

ONCOLINES®

NTRC SYNERGYFINDER™

Apply Combination Studies
to Identify
Novel Synergies

SYNERGYFINDER™

NTRC Mechanistic Cell Biology

Use Cell-Based Assays
to Determine
Mechanism of Action

MECHANISTIC CELL BIOLOGY

PEER REVIEWED PAPERS

Explore Oncolines Expertise via Peer Reviewed Publications and References

View Publications

CASE STUDIES

See Oncolines Precision Medicine Platform in Action

View Case Studies

ONCOLINES NEWS

Check Out Company News
and Press Releases

Read Articles

Recent Oncolines News

Case study – Gene expression profiling to understand and combat drug resistance2022-04-14T11:52:58+02:00
Case study – Gene expression profiling to understand and combat drug resistance

Case study – Gene expression profiling to understand and combat drug resistance

Combination matrix to determine Bliss independence synergy scores2021-11-17T16:21:49+01:00
Combination matrix to determine Bliss independence synergy scores

Combination matrix to determine Bliss independence synergy scores

Case Study – 3D spheroid drug sensitivity2021-10-21T11:35:54+02:00
Case Study – 3D spheroid drug sensitivity

Case Study – 3D spheroid drug sensitivity

Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer2023-01-07T17:10:15+01:00
Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer

Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer

Case study – Synergistic interaction of olaparib and cisplatin2021-10-21T11:38:40+02:00
Case study – Synergistic interaction of olaparib and cisplatin

Case study – Synergistic interaction of olaparib and cisplatin

Case study – TTK patient stratification marker2021-10-21T11:39:08+02:00
Case study – TTK patient stratification marker

Case study – TTK patient stratification marker

Case study – MEK inhibitor2021-10-21T11:39:36+02:00
Case study – MEK inhibitor

Case study – MEK inhibitor

Case study – Kadcyla®2021-10-21T11:40:02+02:00
Case study – Kadcyla®

Case study – Kadcyla®

Case study – CDK4/62021-10-21T11:40:30+02:00
Case study – CDK4/6

Case study – CDK4/6

PREMIUM BENEFITS OF ONCOLINES PRECISION MEDICINE SERVICES: Cell-Based Assays, Drug Combinations, High-Throughput Screening

  • Integration of cancer biology and big data analysis

  • Identification of patient selection markers

  • Side-by-side comparison with known anti-cancer agents

  • Discovery of targeted and novel synergistic drug combinations

  • Science-driven technology platforms

  • Short turnaround times

Oncolines®

How may we help you?